Eric Halioua – President & CEO, PDC*line Pharma
PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last…
Address: Essenscia Diamant Building Bd A. Reyers 80 1030 Brussels, Belgium
Tel: +32 (0)2 238 97 11
essenscia is a multisectoral umbrella organisation that represents the numerous sectors of activities in the field of chemicals and the life sciences. It includes nearly 800 companies representing more than 95% of the overall turnover in the sector.
The structure of essenscia is modelled on the reality of the Belgian institutions, with federal, regional and community areas of competence. essenscia bruxelles, essenscia vlaanderen and essenscia wallonie, the three regional sections of essenscia, act as spokesmen for companies to the Brussels, Flemish and Walloon authorities on regional and community matters. essenscia is made up of multidisciplinary skills centres which also deal with the main issues, irrespective of the level of power. The 17 professional sections of essenscia represent and promote interests specific to their sector of activities.
essenscia represents and defends the sector’s interests at a European level through active involvement in Cefic (the European Council of Chemical Manufacturers’ Federations) and the FEB (Federation of Belgian Companies).
PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last…
Once primarily associated with dispensing medications alone, many pharmacies have now evolved into dynamic healthcare hubs, offering a diverse range of services that extend far beyond traditional prescription filling. Similarly,…
The concepts of patient-centricity and patient-centred healthcare systems have been much discussed in recent years but, in the opinion of Stefan Gijssels, there is still a long road to travel…
Pierre Boyer, GM at Servier BeLux for the past six years, outlines the unique characteristics and challenges of the Belgian market and shares the company’s 2030 strategy, its unique approach…
Gedeon Richter Benelux’s Isabelle de Walsche gives an update on the affiliate’s progress towards becoming a reference player in women’s health, looks back on some of her achievements over 11…
Luc Van Gorp is president of the Christian Mutuality, Belgium’s largest health insurance fund. In a wide-ranging recent conversation with PharmaBoardroom, Van Gorp expanded on some of the key themes…
Xavier De Cuyper of the Federal Agency for Medicines & Health Products (FAMHP), Belgium’s drug regulator, explains the FAMHP’s pandemic response and lessons learned, how the Agency is keeping on…
As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to…
Gábor Sztaniszláv talks through the global relevance of Belux to Amgen’s operations, some of the challenging market access conditions at play – especially for orphan drugs -, and how the…
Marc Gryseels of BACHI, Belgium’s over-the-counter (OTC) medicines association, highlights the organisation’s mission and vision, the key trends at play within the Belgian consumer healthcare market, and his industry’s significant…
Despite the thriving life sciences ecosystem that has made Belgium one of the top European destinations for clinical trials, the country continues to grapple with considerable access challenges and remains…
pharma.be is the association of the Belgian R&D-based pharmaceutical industry, representing over 42,000 employees at 130 companies. CEO Caroline Ven outlines the crucial role that pharma.be and its members played…
See our Cookie Privacy Policy Here